EMAV membership at the meeting on 24th/25th of September in Budapest.
Another significant milestone matched for EMAV
On 24th and 25th of September EMAV members met for an ordinary General Assembly and the 3rd Workshop at Budapest, home country of EMAV member Prophyl Ltd., based in Mohács.
At the general assembly EMAV members accepted ARSIA asbl from Belgium, represented by Christian Quinet, Directeur Laboratoire & Diagnostic, as a new member of the association. In addition the membership agreed to select two additional Board members; Alain Schrumpf, Managing Director of Ceva-Biovac (France) and Maarten de Gussem, Managing Director of Poulpharm BvBA (Belgium).
The meeting was used to establish a Scientific Working Group for EMAV too. This team will - based on a valid experience and comprehensive knowledge about the development, manufacturing and regulation of autogenous vaccines - write the first-draft document of EMAV’s view how the new EU-GMP for autogenous vaccines should look like.
In the workshop, the EMAV members had detailed discussions by hip for the positioning of the association to the REGULATION (EU) 2019/6, the relevant GMP and CMDv guidelines/recommendations for manufacturing of autogenous vaccines. Further, progress was reported on the registration of EMAV as a stakeholder on European level as well as on the soon-to-go live EMAV website.